La Mancha-Centro Hospital
Welcome,         Profile    Billing    Logout  
 2 Trials 
4 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Gomez, Francisco Tadeo
NCT05646017: Effect of Heatwave Over Glycemic Control in Patients With T1D

Completed
N/A
2701
Europe
Intermittenly scanned continuous glucose monitoring, FreeStyle Libre, isCGM, FSL
Castilla-La Mancha Health Service
Type 1 Diabetes
01/23
01/23
UCMODY, NCT05918484: Usefulness of Continuous Glucose Monitoring in MODY Diagnosis

Completed
N/A
500
Europe
Intermittenly scanned continuous glucose monitoring, MODY genetic diagnostic test
Castilla-La Mancha Health Service
Type 1 Diabetes, MODY
01/25
01/25
HEAT1, NCT06214780: Effect of Heatwaves on Glycemic Control in People With Type 1 Diabetes Treated With Artificial Pancreas

Completed
N/A
193
Europe
advanced hybrid closed-loop
Castilla-La Mancha Health Service
Type 1 Diabetes
04/24
05/24
TREAT-MS, NCT03500328: Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial

Active, not recruiting
N/A
900
US
Natalizumab/natalizumab-sztn, Alemtuzumab, Ocrelizumab, Rituximab/rituximab-arrx/rituximab-abbs/rituximab-pvvr, Cladribine, Ofatumumab, Ublituximab-xiiy, Ocrelizumab and hyaluronidase-ocsq, Tysabri, Lemtrada, Ocrevus, Rituxan/Riabni/Truxima/Ruxience, Mavenclad, Kesimpta, Briumvi, Ocrevus Zunovo, Glatiramer acetate, Interferons (intramuscular, subcutaneous, pegylated) Teriflunomide, Fumarates (dimethyl, diroximel, monomethyl) Fingolimod, Siponimod, Ozanimod, Ponesimod, Copaxone, Glatopa, Avonex, Betaseron, Extavia, Rebif, Plegridy, Aubagio, Tecfidera, Vumerity, Bafiertam, Gilenya, Mayzent, Zeposia, Ponvory, Tascenso
Johns Hopkins University, Patient-Centered Outcomes Research Institute, National Multiple Sclerosis Society
Multiple Sclerosis, Relapsing-Remitting
08/26
08/26
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Gomez, Francisco Tadeo
NCT05646017: Effect of Heatwave Over Glycemic Control in Patients With T1D

Completed
N/A
2701
Europe
Intermittenly scanned continuous glucose monitoring, FreeStyle Libre, isCGM, FSL
Castilla-La Mancha Health Service
Type 1 Diabetes
01/23
01/23
UCMODY, NCT05918484: Usefulness of Continuous Glucose Monitoring in MODY Diagnosis

Completed
N/A
500
Europe
Intermittenly scanned continuous glucose monitoring, MODY genetic diagnostic test
Castilla-La Mancha Health Service
Type 1 Diabetes, MODY
01/25
01/25
HEAT1, NCT06214780: Effect of Heatwaves on Glycemic Control in People With Type 1 Diabetes Treated With Artificial Pancreas

Completed
N/A
193
Europe
advanced hybrid closed-loop
Castilla-La Mancha Health Service
Type 1 Diabetes
04/24
05/24
TREAT-MS, NCT03500328: Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial

Active, not recruiting
N/A
900
US
Natalizumab/natalizumab-sztn, Alemtuzumab, Ocrelizumab, Rituximab/rituximab-arrx/rituximab-abbs/rituximab-pvvr, Cladribine, Ofatumumab, Ublituximab-xiiy, Ocrelizumab and hyaluronidase-ocsq, Tysabri, Lemtrada, Ocrevus, Rituxan/Riabni/Truxima/Ruxience, Mavenclad, Kesimpta, Briumvi, Ocrevus Zunovo, Glatiramer acetate, Interferons (intramuscular, subcutaneous, pegylated) Teriflunomide, Fumarates (dimethyl, diroximel, monomethyl) Fingolimod, Siponimod, Ozanimod, Ponesimod, Copaxone, Glatopa, Avonex, Betaseron, Extavia, Rebif, Plegridy, Aubagio, Tecfidera, Vumerity, Bafiertam, Gilenya, Mayzent, Zeposia, Ponvory, Tascenso
Johns Hopkins University, Patient-Centered Outcomes Research Institute, National Multiple Sclerosis Society
Multiple Sclerosis, Relapsing-Remitting
08/26
08/26

Download Options